Perspective Therapeutics, Inc.
CATX
Rank in Stocks
#19783
Perspective Therapeutics, Inc., including its various operations, specializes... Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle β from development and manufacturing to sales and marketing β of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
Share Price
$0.8556
Last synced: 2026-11-09
Market Cap
$97.67M
Change (1 day)
1.86%
Change (1 year)
-61.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Perspective Therapeutics, Inc. (CATX)
Category
Healthcare
EPS for Perspective Therapeutics, Inc. (CATX)
EPS as of June 2026 TTM: $-1.56
According to Perspective Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-1.56. At the end of 2025 the company had an EPS of $-1.40, a decrease compared to its 2024 EPS of $-1.23.
EPS history for Perspective Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.56 | 11.43% |
| 2025 | $-1.40 | 13.82% |
| 2024 | $-1.23 | 44.71% |
| 2023 | $-0.85 | 41.67% |
| 2022 | $-0.60 | 932.70% |
| 2021 | $-0.06 | 20.04% |
| 2020 | $-0.05 | -33.06% |
| 2019 | $-0.07 | -39.75% |
| 2018 | $-0.12 | 9.09% |
| 2017 | $-0.11 | 28.50% |
| 2016 | $-0.09 | 27.57% |
| 2015 | $-0.07 | -52.07% |
| 2014 | $-0.14 | 27.27% |
| 2013 | $-0.11 | -8.33% |
| 2012 | $-0.12 | 9.09% |
| 2011 | $-0.11 | -38.89% |
| 2010 | $-0.18 | -33.33% |
| 2009 | $-0.27 | -27.03% |
| 2008 | $-0.37 | -31.48% |
| 2007 | $-0.54 | -20.59% |
| 2006 | $-0.68 | -10.53% |
| 2005 | $-0.76 | 917.40% |
| 2003 | $-0.07 | -58.50% |
| 2002 | $-0.18 | -130.00% |
| 2001 | $0.60 | -400.00% |
| 2000 | $-0.20 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -273.08% |
US
|
|
| $4.09 | -362.18% |
IE
|
|
| $9.45 | -705.77% |
US
|
|
| $2.37 | -251.92% |
US
|
|
| $1.77 | -213.46% |
US
|
Questions about Perspective Therapeutics, Inc.'s earnings per share (EPS)
What is Perspective Therapeutics, Inc.'s earnings per share (EPS)?
Perspective Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-1.56, as of Jun 2026.
What was Perspective Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Perspective Therapeutics, Inc.'s earnings per share (EPS) was $-1.40, compared with $-1.23 in 2024.
How has Perspective Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Perspective Therapeutics, Inc.'s earnings per share (EPS) was highest in 2020 ($-0.05) and lowest in 2025 ($-1.40).
How does Perspective Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Perspective Therapeutics, Inc.'s earnings per share (EPS) ($-1.56) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.